Sino Biopharmaceutical (Sino Biopharmaceutical) Other Current Liabilities : $981 Mil (As of Dec. 2023)

View and export this data going back to 2010. Start your Free Trial

What is Sino Biopharmaceutical Other Current Liabilities?

Sino Biopharmaceutical's other current liabilities for the quarter that ended in Dec. 2023 was $981 Mil.

Sino Biopharmaceutical's quarterly other current liabilities declined from Dec. 2022 ($937 Mil) to Jun. 2023 ($2 Mil) but then increased from Jun. 2023 ($2 Mil) to Dec. 2023 ($981 Mil).

Sino Biopharmaceutical's annual other current liabilities increased from Dec. 2021 ($807 Mil) to Dec. 2022 ($937 Mil) and increased from Dec. 2022 ($937 Mil) to Dec. 2023 ($981 Mil).

Sino Biopharmaceutical Other Current Liabilities Historical Data

The historical data trend for Sino Biopharmaceutical's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sino Biopharmaceutical Other Current Liabilities Chart

Sino Biopharmaceutical Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Current Liabilities

Get a 7-Day Free Trial

Sino Biopharmaceutical Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Other Current Liabilities	Get a 7-Day Free Trial															-	-	-	-	-

Sino Biopharmaceutical Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

Sino Biopharmaceutical Other Current Liabilities Related Terms

Thank you for viewing the detailed overview of Sino Biopharmaceutical's Other Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Sino Biopharmaceutical (Sino Biopharmaceutical) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sino Biopharmaceutical Ltd (OTCPK:SBMFF) » Definitions » Other Current Liabilities

Comparable Companies

Traded in Other Exchanges

SBHMY:USA 01177:Hong Kong SMZ1:Germany

Address

1 Harbour Road, Unit 09, 41st Floor, Office Tower, Room 4109, Convention Plaza, Wanchai, Hong Kong, HKG

Website

https://www.sinobiopharm.com

Sino Biopharmaceutical Co, or SBP, is one of the largest drugmakers in China, with CNY 27 billion revenue in 2021. Its four most important therapeutic areas are oncology, hepatitis, cardio-cerebral, and respiratory medicines. SBP's current portfolio is mostly generics, and some key drugs are facing severe price reductions. However, it also has a rich pipeline of early-to-market generics and biosimilars, especially in oncology and respiratory treatments.